Immune Checkpoint Inhibitor Toxicity in 2018

JAMA. 2018 Oct 23;320(16):1702-1703. doi: 10.1001/jama.2018.13995.

Authors

Douglas B Johnson^{1

2}, Sunandana Chandra^{3

4}, Jeffrey A Sosman^{3

4}

Affiliations

¹ Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
² Vanderbilt Ingram Cancer Center, Nashville, Tennessee.
³ Department of Medicine, Northwestern University Medical Center, Chicago, Illinois.
⁴ Robert H. Lurie Cancer Center, Chicago, Illinois.

PMID: 30286224
DOI: 10.1001/jama.2018.13995

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents, Immunological / adverse effects*
CTLA-4 Antigen / antagonists & inhibitors*
Chemical and Drug Induced Liver Injury
Colitis / chemically induced
Humans
Immunotherapy / adverse effects
Ipilimumab / adverse effects
Myocarditis / chemically induced
Neoplasms / drug therapy*
Pneumonia / chemically induced
Skin Diseases / chemically induced
T-Lymphocytes / immunology

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
CTLA-4 Antigen
Ipilimumab